title: Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome.
abstract: Ten anemic patients with favorable myelodysplastic syndrome (MDS) were first treated with two 5-week courses of amifostine alone (each course consisted of 200 mg/m(2) of the drug given intravenously three times a week for 3 weeks), followed by an additional two courses combined with subcutaneous erythropoietin (EPO) (150 U/kg, three times a week for 8 weeks). The study patients either had previously failed to respond to treatment with EPO or had pretreatment serum EPO levels of more than 100 mU/ml. None of the patients experienced a complete or partial response in anemia or other cytopenias. We conclude that amifostine alone or in combination with EPO has limited therapeutic activity in MDS.
authors.affiliation: Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA.
authors.forename: A
authors.initials: A
authors.lastname: Tefferi
authors.forename: M A
authors.initials: MA
authors.lastname: Elliott
authors.forename: D P
authors.initials: DP
authors.lastname: Steensma
authors.forename: C C
authors.initials: CC
authors.lastname: Hook
authors.forename: A
authors.initials: A
authors.lastname: Dispenzieria
authors.forename: C A
authors.initials: CA
authors.lastname: Hanson
authors.forename: G
authors.initials: G
authors.lastname: Schroeder
authors.forename: L
authors.initials: L
authors.lastname: Letendre
mesh_terms: D000368:Aged; D004999:Amifostine / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D011994:Recombinant Proteins
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin; D004999:Amifostine